Metformin arrests the progression of established kidney disease in the subtotal nephrectomy model of chronic kidney disease
| Autor: | José B. Lopes de Faria, Victor Ferreira Ávila, Cynthia M. Borges, Guilherme Pedrom Formigari, Clarice Kazue Fujihara, Denise Maria Avancini Costa Malheiros |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Time Factors endocrine system diseases Physiology medicine.medical_treatment Urology Enzyme Activators AMP-Activated Protein Kinases Kidney Nephrectomy 03 medical and health sciences 0302 clinical medicine medicine Renal fibrosis Albuminuria Animals Rats Wistar Renal Insufficiency Chronic Organelle Biogenesis business.industry AMPK medicine.disease Fibrosis Metformin Mitochondria Enzyme Activation Disease Models Animal 030104 developmental biology medicine.anatomical_structure Blood pressure 030220 oncology & carcinogenesis Hypertension Disease Progression medicine.symptom business Kidney disease medicine.drug |
| Zdroj: | American Journal of Physiology-Renal Physiology. 318:F1229-F1236 |
| ISSN: | 1522-1466 1931-857X |
| DOI: | 10.1152/ajprenal.00539.2019 |
| Popis: | Metformin, an AMP-activated protein kinase (AMPK) activator, has been shown in previous studies to reduce kidney fibrosis in different models of experimental chronic kidney disease (CKD). However, in all of these studies, the administration of metformin was initiated before the establishment of renal disease, which is a condition that does not typically occur in clinical settings. The aim of the present study was to investigate whether the administration of metformin could arrest the progression of established renal disease in a well-recognized model of CKD, the subtotal kidney nephrectomy (Nx) model. Adult male Munich-Wistar rats underwent either Nx or sham operations. After the surgery (30 days), Nx rats that had systolic blood pressures of >170 mmHg and albuminuria levels of >40 mg/24 h were randomized to a no-treatment condition or to a treatment condition with metformin (300 mg·kg−1·day−1) for a period of either 60 or 120 days. After 60 days of treatment, we did not observe any differences in kidney disease parameters between Nx metformin-treated and untreated rats. However, after 120 days, Nx rats that had been treated with metformin displayed significant reductions in albuminuria levels and in markers of renal fibrosis. These effects were independent of any other effects on blood pressure or glycemia. In addition, treatment with metformin was also able to activate kidney AMPK and therefore improve mitochondrial biogenesis. It was concluded that metformin can arrest the progression of established kidney disease in the Nx model, likely via the activation of AMPK. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|